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eIF4F complexThe inﬂuenza virus mRNAs are structurally similar to cellular mRNAs nevertheless; the virus promotes selec-
tive translation of viral mRNAs despite the inhibition of host cell protein synthesis. The infection proceeds
normally upon functional impairment of eIF4E cap-binding protein, but requires functional eIF4A helicase
and eIF4G factor. Here, we have studied whether the presence of cis elements in viral mRNAs or the action
of viral proteins is responsible for this eIF4E-independence. The eIF4E protein is required for viral mRNA
translation in vitro, indicating that cis-acting RNA sequences are not involved in this process. We also show
that PB2 viral polymerase subunit interacts with the eIF4G protein. In addition, a chimeric mRNA containing
viral UTR sequences transcribed by the viral polymerase out of the infection is successfully translated inde-
pendently of an impaired eIF4E factor. These data support that the viral polymerase is responsible for the
eIF4E independence of inﬂuenza virus mRNA translation.
© 2011 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza virus uses an unusual transcription mechanism in which
capped and polyadenylated viral mRNAs are synthesized by the viral
polymerase, a heterotrimer composed of three subunits named PA,
PB1 and PB2 (Elton et al., 2005). Viral mRNA synthesis is primed by
short-capped oligonucleotides of around 10 to 12 nucleotides that
are generated from host cell nuclear mRNAs by a viral endonuclease
activity (Plotch et al., 1981). The cap recognition and binding is
achieved by the PB2 subunit (Blaas et al., 1982; Ulmanen et al.,
1981), while the PA subunit seems to be required for the cleavage
of the cap-oligonucleotides (Dias et al., 2009; Yuan et al., 2009). In ad-
dition, the 3′-end of viral mRNAs is polyadenylated by the reiterative
copy of a U5–7 track present near the 5′ end of the genomic negative
sense viral RNA (Luo et al., 1991). Consequently, although synthe-
sized by different pathways, cellular and viral mRNAs are both struc-
turally similar.
Inﬂuenza virus efﬁciently shuts off host cell protein synthesis
(Garﬁnkel and Katze, 1993). Moreover, upon infection, viral mRNAs
are selectively translated (Garﬁnkel and Katze, 1993; Park and
Katze, 1995), while the initiation and elongation of cellular mRNA
translation are inhibited (Katze et al., 1986). The translation initiation
eIF4F complex plays a pivotal role in the translation of capped-
mRNAs. It is a heterotrimer formed by eIF4E, the cap-binding factortecnología, C.S.I.C., Darwin 3,
6.
rights reserved.that is required for cap-dependent translation, the eIF4A helicase
and the scaffolding eIF4G factor. The eIF4G protein binds to eIF3,
which in turn, mediates the recruitment of the 40S ribosomal subunit
triggering the translation initiation of the mRNAs bound to the eIF4F
complex (see, for a review, Gingras et al., 1999). Since viral and cellu-
lar mRNAs are formally equivalent, inﬂuenza virus must have devel-
oped sophisticated strategies to discriminate and favor translation
of its own mRNAs. Among the key factors that have been related
with viral translation regulation, NS1 protein plays an important
role contributing to the selective translation of viral mRNAs in the
infected cell, especially for those produced later in the virus life
cycle. This activation is mediated by its functional interaction with
the 5′ UTR of the viral mRNAs that are conserved in every viral
mRNA (de la Luna et al., 1995; Enami et al., 1994; Park and Katze,
1995). In addition, the interaction of NS1 with the eIF4GI factor
(Aragón et al., 2000) and with the polyA binding protein I (Burgui
et al., 2003) appears to be essential for this process. However, viral
mRNAs are selectively translated in a mutant virus lacking NS1 pro-
tein, suggesting that other viral factors might be involved in the pref-
erential translation of viral mRNAs that takes place within the
infected cells (Salvatore et al., 2002).
Regarding the eIF4F complex, inﬂuenza virus infection alters the
phosphorylation state of eIF4E and eIF4G, and these changes have
been related with the inhibition of host-cell protein synthesis and
the selective translation of viral mRNAs (Feigenblum and Schneider,
1993). In agreement with these data, we have previously shown
that the translation of inﬂuenza virus mRNAs and the viral infection
proceed efﬁciently when the eIF4E cap-binding protein is functionally
Fig. 1. Functional impairment of eIF4E inhibits the in vitro synthesis of inﬂuenza virus
proteins from isolated viral RNAs. (A) Rabbit reticulocyte extracts were depleted of
eIF4E by the addition of puriﬁed 4E-BP1 protein and incubation with a 7mGTP resin.
After removal of the bound complexes, the eIF4E-depleted lysates were used to assess
the translation of in vitro transcribed cap-CAT:EMCV-IRES-Luc RNA or puriﬁed cytoplas-
mic RNA from infected cells (−4E lanes). Subsequently, puriﬁed His-eIF4E recombinant
protein was added (+4E lanes). The bottom panel shows the amounts of the indicated
proteins in the eIF4E-depleted preparations and after the addition of recombinant His-
eIF4E protein. The synthesized proteins were metabolically labeled and analyzed by
SDS-PAGE. (B) Cytoplasmic RNA from HEK293T infected cells isolated after 6 hpi and
dicistronic cap-CAT:EMCV IRES-Luc RNA obtained by in vitro transcription were used
for in vitro translation in reticulocyte lysates, with or without increasing concentrations
of puriﬁed 4EBP1. The bottom panel shows the amounts of 4EBP1 added to the reac-
tions. The synthesized proteins were processed as described in part (A).
298 E. Yángüez et al. / Virology 422 (2012) 297–307impaired, even when a recombinant inﬂuenza virus lacking NS1 pro-
tein is used (Burgui et al., 2007). In addition, we have recently charac-
terized that the other two components of the eIF4F complex, eIF4A
and eIF4G, are essential for viral translation both in in vivo and in
vitro analyses and, hence, should not be related with selective trans-
lation in the infected cell (Yángüez et al., 2011).
Among the possible trans-acting proteins that could be involved in
viral protein synthesis, we also described that the inﬂuenza virus po-
lymerase binds to translation preinitiation complexes and that the in-
fection increases the binding of the eIF4GI factor to cap-structures
under conditions of eIF4E–eIF4GI disassociation triggered by overex-
pression of a non-phosphorylatable 4E-BP1 protein (Burgui et al.,
2007). These data suggest a role for the viral polymerase in overriding
the dependence of viral mRNA translation on the eIF4E factor, as it
could behave as the cap-binding factor that mediates eIF4G recruit-
ment to the viral mRNA. Here, we have assessed whether the viral po-
lymerase or the presence of cis structural elements in viral mRNAs is
the responsible for the eIF4E independence. This process could be
part of the mechanism underlying the selective translation of viral
mRNAs that takes place in the infected cell.
Results
Study of the presence of structural cis elements in inﬂuenza virus mRNAs
As mentioned, inﬂuenza virus infection proceeds normally in the
absence of functional eIF4E factor. Thus, rapamycin treatment, eIF4E
gene silencing and overexpression of constitutively hypophosphory-
lated 4E-BP1, which provokes eIF4E–eIF4G dissociation, do not impair
viral mRNA translation in the infected cells (Burgui et al., 2007). Com-
mon structural determinants within inﬂuenza virus mRNAs could
mediate their independence for the cap-binding factor as, for in-
stance, internal ribosome entry sites (IRES) that are capable of direct-
ly recruiting the translation machinery (Kieft, 2008; Martinez-Salas et
al., 2008). Therefore, we carried out in vitro experiments to examine
whether inﬂuenza virus mRNAs contain sequences that would confer
eIF4E independence.
Requirements for eIF4E in vitro
We compared the translation efﬁciency of a dicistronic cap-CAT-
EMCV:IRES-luciferase RNA containing the encephalomyocarditis dis-
ease virus IRES, with isolated RNAs from inﬂuenza virus infected
cells in conditions of limited eIF4E availability. Accordingly, in vitro
translation preparations were depleted of eIF4E by adding puriﬁed
4E-BP1 protein followed by incubation with a cap-Sepharose resin.
After removal of the bound complexes by centrifugation, the eIF4E-
depleted lysates were used to translate in vitro transcribed cap-CAT:
EMCV-IRES-Luc RNA or puriﬁed cytoplasmic RNA from infected cells
(Fig. 1A). The depletion of eIF4E produced a clear decrease in cap-
dependent CAT protein synthesis, while IRES-driven luciferase syn-
thesis remained unaffected. Similarly, the synthesis of viral proteins
diminished under these conditions. Further addition of puriﬁed re-
combinant His-eIF4E protein partially recovered the translation of
CAT and viral proteins in the eIF4E-depleted preparations.
We also used a different approach to analyze the possible pres-
ence of speciﬁc structures in the viral mRNAs that might be involved
in the low dependence on eIF4E. Accordingly, both in vitro transcribed
dicistronic cap-CAT:EMCV-IRES-Luc RNA and cytoplasmic RNA from
infected cells were then assayed in the presence or absence of in-
creasing concentrations of puriﬁed 4E-BP1 to inhibit the interaction
of eIF4E with eIF4G. The proteins synthesized were metabolically la-
beled and analyzed by SDS-polyacrylamide gels (SDS-PAGE)
(Fig. 1B). Translation of the IRES-driven luciferase was not affected
by the addition of 4E-BP1 even at the highest doses. By contrast, the
translation of the CAT gene, which occurs in a cap-dependentmanner, clearly diminished in the presence of 4E-BP1. Similarly, the
addition of puriﬁed 4E-BP1 signiﬁcantly reduced the translation of
viral mRNAs. These results indicate that isolated inﬂuenza virus
mRNAs behave like standard capped-mRNAs in terms of eIF4E depen-
dence in vitro. Therefore, the low requirement for functional eIF4E ob-
served in vivo is not due to an inherent property of the viral mRNA
(e.g. the presence of cis elements), but it is more likely the conse-
quence of speciﬁc factors acting in trans.
299E. Yángüez et al. / Virology 422 (2012) 297–307The PB2 inﬂuenza virus polymerase subunit interacts with the eIF4GI
factor
We previously reported that the inﬂuenza virus polymerase com-
plex, both from inﬂuenza virus infected cells or expressed from cloned
cDNAs, co-immunoprecipitates with the translation initiation factor
eIF4GI (Burgui et al., 2007). To further characterize this interaction,
viral polymerase subunits were individually expressed and their ability
to associate with eIF4GI was evaluated. Thus, HEK293T cells wereFig. 2. PB2 inﬂuenza virus polymerase subunit associates with eIF4GI. (A) HEK293T cells wer
were prepared and used for immunoprecipitation assays using anti-eIF4GI or a control ant
probed with antibodies against the indicated proteins. (B) Scheme of the HA-tagged PB2 pr
mids and immunoprecipitation assays were performed as indicated in (A). The Western blotransfected with pCMV plasmids expressing each of the subunits and
24 h later, cell extracts were analyzed by co-immunoprecipitation
using speciﬁc antibodies against eIF4GI or with a control serum. The
PB2 subunitwas present in the immunocomplexeswith eIF4GI,whereas
the PA or PB1 subunits were undetected. In addition, the presence of
eIF4E in the eIF4GI immunoprecipitates was evaluated as positive con-
trol of interacting proteins (Fig. 2A). Next, we mapped the region in
the PB2 subunit required for this association. This was achieved by
using clones of a pCDNA-HA plasmid containing PB2 N-truncatede transfected with plasmids expressing PA, PB1, or PB2 and 24 h later, cytosolic extracts
ibody. The immunoprecipitates were separated by SDS-PAGE, and Western blots were
oteins used in part C. (C) HEK293T cells were transfected with the corresponding plas-
t was probed with anti eIF4GI and anti HA antibodies.
300 E. Yángüez et al. / Virology 422 (2012) 297–307fragments. The different fragments used are soluble when expressed in
Escherichia coli as they were obtained by a high-throughput screening
method known as expression of soluble proteins by random incremen-
tal truncation (ESPRIT) (Tarendeau et al., 2007; Yumerefendi et al.,
2010). HEK293T cells were transfected with these constructs and 24 h
later, the proteins were immunoprecipitated with speciﬁc anti-eIF4GI
or an unrelated antibody and analyzed in Western blots probed with
an anti-HA antibody. The results indicate that the PB2 sequence that
mainlymediates the associationwith eIF4GI resides in its C-terminal re-
gion between amino acids 538–693 (Figs. 2B–C), a domain that maps
out of the minimal region involved in cap association (318–483)
(Guilligay et al., 2008).
Many cellular proteins associate with the eIF4GI translation initia-
tion factor and therefore they could mediate its interaction with PB2
and the viral polymerase. To discriminate between a direct or indirect
association of eIF4GI and PB2, both proteins were expressed as His
tagged-proteins in bacteria and after puriﬁcation they were eluted
from the afﬁnity resins and their association was examined. Puriﬁca-
tion of His-eIF4GI and His-PB2 proteins was evaluated by Western
blots using both speciﬁc antibodies against the corresponding pro-
teins and anti-His antibodies. The results are presented in Fig. 3A;
both proteins were expressed as entire recombinant proteins, al-
though degradation products or fragments generated by premature
termination were also present. For coimmunoprecipitation analysis
His-eIF4GI and His-PB2 were incubated to allow their interaction
and then immunoprecipitation assays were performed with anti-
bodies against eIF4GI or the preimmune serum. The speciﬁc anti-
eIF4GI antibody immunoprecipitated His-eIF4GI as well as His-PB2
when it was incubated with eIF4GI (Fig. 3B). By contrast, the preim-
mune serum did not immunoprecipitate either His-eIF4GI or His-
PB2 from the incubation mixture and the eIF4GI antibody did not im-
munoprecipitate the His-PB2 alone. These results indicate that eIF4GIFig. 3. PB2 and eIF4GI interact directly. (A) Recombinant His-eIF4GI (left) and His-PB2
(right) proteins expressed and puriﬁed from bacteria were analyzed by Western blot-
ting with speciﬁc (Ab-eIF4GI and Ab-PB2) and anti-His antibodies. (B) Interaction of
eIF4GI and PB2 proteins. Puriﬁed His-eIF4GI and His-PB2 proteins were tested for im-
munoprecipitation with preimmune or anti-eIF4GI antibodies when they were incu-
bated alone (His-eIF4GI or His-PB2) or when both proteins were incubated together
(His-eIF4GI+His-PB2) and the immunocomplexes analyzed by Western blotting
with the indicated antibodies.and PB2 establish a direct association not mediated by other cellular
proteins.
To further characterize the region of eIF4GI that interacts with
PB2, a pep-spot analysis was carried out. This technique was previ-
ously described as a method to detect linear epitopes recognized by
antibodies (Kaikkonen et al., 1999; Valle et al., 1999) and it can be
used to map protein–protein interactions when a particular structural
conformation is not required for the interaction (Huarte et al., 2001).
Thus, a nitrocellulose membrane was prepared containing sequential
overlapping peptides of 13 amino acids covering the entire sequence
of eIF4GI, with a 3-amino-acid shift with the next peptide.
Recombinant His-PB2 protein expressed and puriﬁed from bacteria
was incubated with the membrane and its possible binding was ex-
amined by Western blot. As a control, recombinant His-VP1 protein
from infectious bursal disease virus expressed and puriﬁed from bac-
teria (Garriga et al., 2007) was used (Fig. 4A). Prior to probing with
His-PB2 and His-VP1, the membrane was probed with the corre-
sponding primary and secondary antibodies to detect the unspeciﬁc
spots (Fig. 4B, top panels) and subsequently, the membrane was incu-
bated with the His-tagged proteins. The sequence of incubations is
described in Materials and methods and the results are presented in
Fig. 4B. To avoid possible false-positives resulting from the speciﬁc
characteristics of individual peptide spots, we have used restrictive
criteria, assuming only as positive interacting regions those having
positive signals in at least 19 amino acids (3 consecutive spots).
With these criteria, puriﬁed His-PB2 protein binds to at least two re-
gions of eIF4GI, between amino acids 664–681 and 1114–1131
(marked by arrows) (Fig. 4B, bottom panels). It should be noted
that in this assay the peptides are distributed in the membrane
according to their linear sequence location, but separated positive
peptides could be close in the native folded protein. The ﬁrst positive
sequence includes the recognition and processing site of enterovirus
2A and picornaviruses L proteases (Foeger et al., 2002; Gradi et al.,
2004; Lamphear et al., 1995; Sousa et al., 2006) indicating that this se-
quence should be exposed and accessible. The second putative site re-
sides within a region where no other eIF4GI-binding proteins have
been described. No speciﬁc His-VP1-eIF4GI interaction was detected.
These data indicate that the eIF4GI–PB2 interaction is direct and not
mediated by viral RNA or any of the previously described eIF4G-
interacting factors.The role of the viral polymerase in viral mRNA translation
Several observations such as: I) the cap-binding properties of the
viral polymerase; II) the fact that the inﬂuenza virus polymerase com-
plex binds to the highly conserved 5′ UTR sequence common to all
viral genes in vitro (Shih and Krug, 1996); III) the association of the
viral polymerase with eIF4GI and the direct interaction of the PB2
cap-binding subunit with this factor; IV) the recruitment of eIF4GI
and the polymerase to cap analogs upon infection under conditions
of eIF4E–eIF4G disassociation (Burgui et al., 2007); and V) the hypo-
phosphorylation of eIF4E factor that takes place during the infection
and should decrease the eIF4E–eIF4G association (Feigenblum and
Schneider, 1993), have been considered. Taken together, these data
suggest a role for the viral polymerase in viral translation modulation,
probably replacing the eIF4E function during the translation of viral
mRNAs.
To address this possibility, we compared the requirements for
eIF4E on the translation of a reporter mRNA expressing CAT, contain-
ing viral 5′ and 3′ UTR sequences when it is expressed either by the
viral polymerase or by the cellular RNA polymerase II. The experi-
mental design is shown in Fig. 5. Brieﬂy, HEK293T cells were trans-
fected with plasmids expressing the viral RNP components PA, PB1,
PB2 and NP, and incubated for 18 h to allow the accumulation of
these proteins. Then, the cells were maintained in the presence or
Fig. 4. Mapping of PB2 interaction within the eIF4GI sequence. (A) Coomassie staining of His-PB2 and His-VP1 proteins expressed and puriﬁed from bacteria. Asterisks represent
PB2 degradation products or PB2 fragments generated from premature termination since they are detected with the anti-PB2 antibody (data not shown). (B) A collection of 122
overlapping peptides representing the complete eIF4GI factor was synthesized on a cellulose membrane, which was incubated sequentially in the presence or absence of puriﬁed
His-proteins and the corresponding primary and secondary antibodies, and assayed in Western blots. After each incubation the membrane was stripped and used for the next de-
tection. The sequence of incubation was as follows: primary and secondary antibodies used to detect PB2 (top, left); incubation with His-PB2 protein followed by its corresponding
primary and secondary antibodies (bottom, left); primary and secondary antibodies used to detect VP1 (top, right); and ﬁnally His-VP1 followed by its corresponding primary and
secondary antibodies (bottom, right). The arrows represent eIF4GI–PB2 interacting peptides. (C) Representation of the PB2 interaction sites in the eIF4GI sequence.
301E. Yángüez et al. / Virology 422 (2012) 297–307absence of rapamycin. Some cells were subsequently transfected with
a plasmid expressing the CAT gene driven by an RNA polymerase II
promoter, with or without the 5′ and 3′ UTR sequences of the NS seg-
ment of viral mRNA (pCMV-NS-CAT and pCMV-CAT respectively:
Figs. 5A–B). Other cells were next transfected with puriﬁed, active
viral RNPs that were reconstituted in vivo with a vRNA-like CAT
gene that contains the same 3′ and 5′ UTRs of the vRNA of NS segment
(prepared as described in Supp. Inf. 1) (Jorba et al., 2009) (Fig. 5C). At
7 h post transfection, samples were collected and used for CAT analy-
sis and RNA detection. In summary, the cells in the three experimen-
tal conditions express the viral RNP components, but two of them
express a CAT mRNA transcribed from the RNA polymerase IIpromoter (with or without UTR viral sequences), while the other ex-
presses the CAT mRNA by the action of the viral polymerase.
First, we evaluated whether similar polymerase complexes are
formed under the different experimental conditions depicted in
Figs. 5B and C. To that aim, some HEK293T cells were transfected
with plasmids expressing PA, PB1 and a His-tagged PB2 protein, incu-
bated for 18 h and after that, transfected with the pCMV-NS-CAT plas-
mid. Other cells were transfected with plasmids that express PA, PB1
and PB2-His with or without NP, incubated for 18 h and transfected
with the pHH-NS-CAT plasmid used to reconstitute active viral
RNPs. After transfection, the viral polymerase complexes were puri-
ﬁed by 2+Ni-NTA-agarose afﬁnity chromatography and the presence
Fig. 5. Scheme used for the evaluation of eIF4E dependence on CAT expression driven by RNA polymerase II or by the viral polymerase. In Parts A and B we evaluated whether the
presence in trans of the viral polymerase confers rapamycin resistance to a cellular-like CAT mRNA (pCMV-CAT) or a viral-like CAT mRNA (pCMV-NS-CAT), both transcribed by the
cellular RNA polymerase II. In Part C we examined whether the translation of a viral-like CAT mRNA transcribed by the viral polymerase is rapamycin insensitive. In this case, the
antisense CAT vRNA was previously used to reconstitute and purify viral RNPs (NS-CAT-vRNPs). These NS-CAT-vRNPs were then transfected in cells expressing the polymerase and
the NP proteins and, therefore, the corresponding CAT-mRNA was synthesized by the inﬂuenza virus polymerase.
302 E. Yángüez et al. / Virology 422 (2012) 297–307of polymerase components and NP evaluated by SDS-gels followed by
Western blots. Under the different experimental conditions the
amount of polymerase subunits that associate and form polymerase
complexes is similar, independent of the nature of the ﬂu-like viral
RNA (sense or antisense) expressed and the formation of viral RNPs
that should occur when PA, PB1, PB2-His, NP and pHH-NS-CAT are
used for transfection (Supp. Inf. 2).
To evaluate the efﬁcacy of the rapamycin treatment treated and
untreated cells were labeled in vivo and the proteins were resolved by
SDS-PAGE. As expected, rapamycin treatment reduced the phosphoryla-
tion of 4E-BP1 protein at Ser65 (Fig. 6A), which has been correlatedwith
an increase in its afﬁnity for eIF4E (Gingras et al., 1999) and the disrup-
tion of eIF4E–eIF4G association (Gingras et al., 2004). Consequently,
rapamycin produced a reduction of around 30% in the 35S-Met incorpo-
ration, which is similar to that observed in NIH3T3 cells (Maeshima
et al., 2002). Together, the reduced incorporation of 35S-Met and the
pattern of 4E-BP1 phosphorylation, indicate that rapamycin produced a
decrease in eIF4E-dependent translation. Under these conditions, no
major differences in the accumulation of the RNP components were
found in the rapamycin treated cells compared with the untreated
cells, as a signiﬁcant amount of these proteins was accumulated during
18 h previously to rapamycin addition (data not shown).
In order to discard possible differences in CAT protein after rapamy-
cin treatment as a consequence of variation in the mRNA amount, the
levels of CAT encoding mRNA were determined by qRT-PCR in the dif-
ferent experimental conditions. No signiﬁcant variations on CAT
mRNAs were found between treated or untreated cells in any of the ex-
perimental conditions (Fig. 6B). Next, we tested the CAT protein pro-
duced under the different conditions and the results are presented in
Fig. 6 C. Exposure to rapamycin resulted in a reduction of around 20%
in the amount of CAT protein generated from the expression of
pCMV-CAT and pCMV-NS-CAT plasmids. This reduction is in agreementwith the observed inhibition in the general protein synthesis by 35S-Met
incorporation (Fig. 6A) and with previous publications on the effect of
rapamycin on translation inhibition, since, depending on the system
the degree of inhibition ranges from nearly undetectable (Feldman et
al., 2009; Thoreen et al., 2009) to 50% in the most severe cases
(Beretta et al., 1996; Kumar et al., 2000; Maeshima et al., 2002). By con-
trast, CAT protein accumulation was increased by around 20% when
produced from an mRNA transcribed by the viral polymerase (results
were obtained consistently and repeatedly in more than six indepen-
dent experiments, each performed in triplicate).
Finally, to obtain the actual translational efﬁciency in the different
situations, the corresponding CAT protein/CAT mRNA ratios were
obtained (Fig. 6D). As can be seen, the translation of a CAT mRNA
transcribed by the viral polymerase is insensitive to the functional
impairment of eIF4E factor induced by the rapamycin treatment.
Moreover, CAT mRNA translation is augmented in this situation and
this increase could reﬂect a reduction in the competition for eIF4GI
binding, as capped mRNAs are not being efﬁciently translated and
therefore, for the translation initiation complexes.
It is important to emphasize that the presence in trans of the protein
components of the RNPs together with the vRNA-like model (NS-CAT
condition) transcribed by the RNApolymerase II, does not confer rapamy-
cin independence (Fig. 6D). Therefore, transcription of the chimeric viral
mRNA by the viral polymerase is required to confer eIF4E independence.
To evaluate the involvement of viral polymerase on viral mRNA
translation by a different approach, we performed similar experi-
ments blocking cap-dependent translation by overexpression of the
4E-BP1 protein by plasmid transfection, instead of treating with rapa-
mycin. Under these conditions the translational rates were similar to
those obtained upon rapamycin treatment, but variations in the accu-
mulated mRNAs were observed making more difﬁcult the acquisition
of accurate results (data not shown).
Fig. 6. Viral polymerase confers eIF4E independence. HEK293T cells were processed as described in Fig. 5. (A) Metabolic labeling of treated and untreated cells with rapamycin. The
right panel shows 4E-BP1 phosphorylation on Ser 65. (B) CAT mRNA accumulation measured by RT-PCR. (C) CAT protein accumulation in the different conditions described in Fig. 5.
(D) Rates of CAT protein/CAT mRNA accumulation in each condition described in Fig. 5. Standard deviations are indicated by bars, asterisks (*=pb0.05) indicate statistical signif-
icance determined by Student's T-test. (E) Representation of the relative translation efﬁciency presented in part (D).
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Most of the mechanisms involved in translational modulation are
focused on the translation initiation step. Among them, regulation of
the eIF4F complex through its phosphorylation, which modulates the
association of its various components, is frequently observed. Within
the eIF4F complex, the eIF4G factor plays a pivotal role acting as a
scaffolding protein that triggers the ribosome recruitment to the
mRNAs to which it is bound. Numerous viruses encode proteins that
play an important role in the translational control of their own
mRNAs, interfering with cellular mRNA translation and indeed some
of them supplant the function of some eIF4F components. A good
example is the NSP3 protein of rotavirus, which binds to eIF4G and
the 3′ end of viral mRNAs, disrupting eIF4G–PABP1 binding andinhibiting the translation of cellular mRNA (Piron et al., 1998). Ade-
novirus also offers an example of a protein that obstructs cellular
translation. It encodes a 100 k protein that binds to eIF4G and dis-
rupts the eIF4G–Mnk1 interaction, thereby inhibiting the phosphory-
lation of eIF4E, which cooperate in the inhibition of host protein
synthesis (Cuesta et al., 2000). Other viruses encode proteins that
mimic different components of translation related factors. The N pro-
tein of hantaviruses, which use an orthomyxovirus-like cap-snatching
mechanism to yield mRNAs with 5′ caps derived from cellular mRNAs
(Dunn et al., 1995; Hutchinson et al., 1996), replaces, not only eIF4E
function, but also eIF4A and eIF4G (Mir and Panganiban, 2008). Dur-
ing viral translation, the N protein binds to the cap structures of viral
mRNAs and to the 43S pre-initiation complex, facilitating loading of
ribosomes onto viral capped mRNA. This list of such proteins is now
304 E. Yángüez et al. / Virology 422 (2012) 297–307expanded with the contribution of the inﬂuenza virus polymerase,
which seems to replace the cellular cap-binding factor eIF4E for
viral mRNA translation.
Inﬂuenza virus mRNA translation
Translation of cellularmRNAs is strongly inhibited in inﬂuenza virus-
infected cells (Skehel, 1972). The dephosphorylation of eIF4E triggered
by the infection (Feigenblum and Schneider, 1993; Katze et al., 1984),
which strongly correlates with decreased rate of translation in many
systems (Scheper and Proud, 2002), could be at least in part, involved
in this phenomenon. Despite the capped nature of inﬂuenza virus
mRNAs, their translation seems to be independent of functional eIF4E
proteinwithin the infected cells (Burgui et al., 2007). Furthermore, inﬂu-
enza virus infection efﬁciently progresses in adenovirus infected cells,
despite the strong dephosphorylation of eIF4E induced by adenovirus
infection (Zhang et al., 1994). Therefore, translation of inﬂuenza
virus mRNAs may escape from the viral-induced inhibition of cap-
dependent initiation. However translation of inﬂuenza virus mRNAs
requires the participation of the two other components of the eIF4F
complex, the eIF4A helicase and the eIF4G scaffold protein (Yángüez
et al., 2011). These results discard a potential direct recruitment of the
40S ribosomal subunit to the viral mRNAs, which would confer eIF4F-
independence and indicate that coupling of inﬂuenza virus mRNAs to
eIF4G is absolutely required for efﬁcient viral translation.
Role of the viral polymerase
We have provided evidence that the viral polymerase interacts
with translation initiation complexes (Burgui et al., 2007). The viral
polymerase co-immunoprecipitates with eIF4GI both in inﬂuenza
virus infected cells and when recombinant polymerase subunits
were expressed by transfection (Burgui et al., 2007). Furthermore,
using experimental conditions in which the association of eIF4GI to
the cellular cap-binding factor eIF4E protein is reduced, the inﬂuenza
virus infection speciﬁcally increases the association of eIF4GI with the
cap structures (Burgui et al., 2007). Here, we show that the PB2 cap-
binding subunit interacts with eIF4GI (Figs. 3 and 4) and therefore, it
could mediate the association of the polymerase complex with the
translation initiation eIF4F complex.
The characterization of the role of the inﬂuenza virus polymerase
in the modulation of viral protein synthesis has shown that the trans-
lation of a viral ﬂu-like mRNA, whose expression is driven by the viral
polymerase, behaves similarly to that of the viral mRNAs in the
infected cells in terms of eIF4E independence. In fact, an increase in
the translation of this viral ﬂu-like mRNA occurs under conditions of
eIF4E–eIF4G dissociation (Fig. 6). The availability of eIF4E appears
to play a critical role in the switch from cap-dependent to IRES-
mediated translation in picornavirus-infected cells. It has been
reported that in picornavirus-infected cells where both capped and
IRES-containing mRNAs are present, a decrease in the amount of
eIF4E associated with the eIF4F complex elicits a striking increase in
IRES-mediated viral mRNA translation (Svitkin et al., 2005). This effect
is not observed in translation extracts depleted of capped mRNAs, in-
dicating that capped mRNAs compete with IRES-containing mRNAs
for translation (Svitkin et al., 2005). These data parallel the observa-
tions during inﬂuenza virus infection since the reported eIF4E dephos-
phorylation should decrease the eIF4E–eIF4G association and viral
mRNAs might associate with the eIF4G/4A subcomplex via the PB2–
eIF4G interaction, resembling the behavior of the IRES.
Model for viral mRNA translation
As suggested by different authors, preferential translation of viral
mRNAs could rely on the speciﬁc interaction of the viral 5′-UTR with a
selective factor present in the infected cell. Viral polymerase interactswith the 5′ UTR sequences common to all viral segments in vitro (Shih
et al., 1995). This interaction has been proposed as a way to protect
the viral mRNAs during the cap-snatching process. Moreover, the poly-
merase complex from extracts of infected cells binds to cap structures
with greater afﬁnity than eIF4E does and accordingly, m7GTP is 200-
fold less potent cap binding inhibitor for the inﬂuenza virus polymerase
than for the eIF4E factor (Hooker et al., 2003). Therefore, the viral poly-
merase could associate to the capped 5′UTR sequences of the viral tran-
scripts, even in the presence of the cap-binding complex (CBC) or eIF4E.
This is feasible and in fact, the polymerase binds to the cap-structures of
cellular pre-mRNAs in the presence of the CBC complex during the ini-
tiation of viral transcription. On the other hand, the presence of inﬂuen-
za virus polymerase complexes free of nucleoprotein, both in the
nucleus and cytoplasm of the infected cells, has been reported (Detjen
et al., 1987).
As described above although viral mRNAs can overcome the viral-
induced eIF4E dephosphorylation they need a functional eIF4G factor
to be successfully translated (Burgui et al., 2007; Yángüez et al.,
2011). Therefore, collectively, the data support a model in which in-
ﬂuenza virus polymerase, bound to the cap and the 5′-UTR common
viral sequence, would replace eIF4E function and speciﬁcally recruit
translation machinery to the viral mRNAs. The association of the
viral polymerase and eIF4GI may be involved in the preferential
translation of viral mRNAs during inﬂuenza infection. In addition,
the interaction of NS1 with the translation initiation factors eIF4GI
(Aragón et al., 2000) and PABP1 (Burgui et al., 2003) could promote
the formation of a “closed loop” between the 5′ and 3′ ends of the
viral mRNA.
Finally, as for the aforementioned examples of other viruses, inﬂu-
enza virus seems to enlarge the list of viruses that possess proteins
that can modulate the translation of viral proteins by speciﬁcally as-
sociating with translation initiation complexes. In this particular
case two viral proteins, PB2 and NS1, and two cellular translation re-
lated factors, eIF4GI and PABP1, appear to facilitate the speciﬁc trans-
lation of viral mRNAs, contributing to the optimal synthesis of
proteins during the viral cycle.
Materials and methods
Biological materials
The HEK293T cell line and the inﬂuenza virus A/Victoria/3/75 (VIC)
strainwere used throughout these studies, aswere the plasmids pCMV-
PA, pCMV-PB1, pCMV-PB2 and pCMV-NP (Falcón et al., 2004). J.J. Sanz-
Ezquerro supplied plasmid pRSET-PB2 that expresses a recombinant
His-PB2 protein. Plasmids pCMV-PB2-His and pRSET-eIF4GI157-1553
expressing recombinant PB2-His and an N-terminal truncated His-
eIF4GI proteins have been previously described (Jorba et al., 2009, Ara-
gón, 2000 #1070). Plasmids pCDNA3-HA-PB2 (318–483), pCDNA3-HA-
PB2 (538–693) and pCDNA3-HA-PB2 (538–759) were provided by D.
Hart. The plasmid expressing, by an RNA polymerase I promoter, the
CAT gene ﬂanked with the UTR sequences of inﬂuenza virus segment
8 in antisense orientation (pHH-NS-CAT) was kindly provided by A.
Rodriguez. The plasmid expressing the CAT gene with the UTR se-
quences of segment NS expressed by the RNA polymerase II promoter
(pCMV-NS-CAT) was constructed by insertion of the NS-CAT fragment
frompHH-NS-CAT into the pCDNA5plasmid. E.Martínez-Salas supplied
the plasmid expressing the CAT protein without the viral UTRs (pCMV-
CAT). Complete protease inhibitors and RNase (human placenta RNAse
inhibitor) inhibitor were obtained from Roche and rapamycin was
bought from Calbiochem.
Transfection and virus infection
All infections were carried out at a multiplicity of infection of 3
PFU/cell and when necessary, HEK293T were previously transfected
305E. Yángüez et al. / Virology 422 (2012) 297–307by the calcium–phosphate method (Wigler et al., 1979). At different
times post-infection, cells were used for immunoprecipitation, meta-
bolic labeling, RT-PCR or CAT Elisa (Roche) studies.
Western blotting
Western blotting was performed as described previously (Aragón
et al., 2000). The following primary antibodies were used: for transla-
tion initiation factor eIF4GI, a mixture of four rabbit polyclonal anti-
bodies (1:8.000 each) (Aragón et al., 2000); for eIF4E, a monoclonal
antibody from Transduction Laboratories (1:2.000); for PA, monoclo-
nal antibodies 2 and 9 (1:20 each) (Bárcena et al., 1994); for PB1, a rat
polyclonal antibody (1:1.000) (Coloma et al., 2009); for PB2, mono-
clonal antibodies 8 and 28 (1:100 each) (Bárcena et al., 1994);
for NP, a rabbit polyclonal antibody (1:5.000) (Coloma et al., 2009);
for the His tag, a rabbit polyclonal antibody (1:10.000) from Sigma;
for VP1, a rabbit polyclonal antibody (1:1000) (a gift from J. F.
Rodríguez); for ß-tubulin, a mouse monoclonal antibody (1:50.000)
from Sigma; for HA, a mouse monoclonal antibody (1:1.000) from
Abcam and for 4E-BP1 a goat polyclonal antibody (1:200); and 4E-
BP1 P-Ser65, a rabbit polyclonal antibody (1:200) both from Santa
Cruz Biotechnology.
Expression and puriﬁcation of recombinant proteins
Recombinant plasmids expressing the His-4E-BP1 or His-eIF4E
proteins were generously supplied by S. Morley (University of
Sussex) and S. Curry (Imperial College London), respectively. The re-
combinant proteins were puriﬁed by afﬁnity chromatography on a
Hitrap chelating column (GE Healthcare).
To perform eIF4GI–PB2 interaction and pep-spot analysis, the His-
PB2 protein and the His-eIF4GI protein that contains the eIF4GI se-
quence lacking the ﬁrst 157 amino acids (Aragón et al., 2000), were
expressed in E. coli BL21DE3 pLysS cells harboring the corresponding
pRSET recombinant plasmids. After induction for 27 h at 16 °C with
IPTG (10 mM) for His-PB2 expression or 2 h at 37 °C for His-eIF4GI
expression with IPTG (1 M), the cells were resuspended in a buffer
containing 50 mM Tris–HCl (pH-8.0), 500 mM NaCl, 5 mM MgCl2,
10% glycerol, 0.1% NP40 and 100 mM imidazol (supplemented before
use with “Complete” and 10 mM 2ME) and they were sonicated. After
removal of the cell debris by centrifugation, the supernatant was in-
cubated overnight at 4 °C with 2+Ni-NTA-agarose resin (Invitrogen)
equilibrated in the same buffer with gentle rocking. After extensive
washes with 20 mM Tris–HCl (pH-8.0), 0.1 M KCl, 5 mM MgCl2, 10%
glycerol, 10 mM 2ME and 50 mM imidazole (washing buffer), the
proteins were eluted with 1 M imidazole in washing buffer. The con-
trol protein His-VP1 was puriﬁed as described previously (Garriga et
al., 2007).
Analysis of viral polymerase subunits associated with eIF4GI factor
HEK293T cells were transfected with the plasmids pCMVPB1,
pCMVPB2 or pCMVPA and 24 h later, cytosolic extracts were prepared
in buffer A (150 mM NaCl, 1.5 mM MgCl2, 10 mM Tris–HCl (pH 8.5),
0.2% Igepal) with complete protease inhibitor and phosphatase inhib-
itors (5 mM Na3VO4, 5 mM ß-glycerophosphate, 5 mM sodium mo-
lybdate) plus human placenta RNAse inhibitor (1:1.000). After
centrifugation at 10.000×g, the supernatants were collected and
used for immunoprecipitation studies. The cell extracts were incubat-
ed with a speciﬁc anti-eIF4GI antibody or pre-immune serum as
reported previously (Aragón et al., 2000) and after incubation, they
were washed 10 times with buffer A and analyzed by SDS-PAGE and
Western blotting.
To map the interaction domain of the PB2 subunit with eIF4GI,
HEK293T cells were mock transfected or transfected with pCDNA3-
HA-PB2 (318–483), pCDNA3-HA-PB2 (538–693) or pCDNA3-HA-PB2 (538–759) and, 24 h later, cytosolic extracts were prepared in
buffer A containing proteases, phosphatases, and RNase inhibitors.
After centrifugation at 10.000×g, the supernatants were collected
and used for co-immunoprecipitation studies as described above.
To examine the eIF4GI–PB2 interaction, puriﬁed His-PB2 and His-
eIF4GI proteins were incubated in buffer A with 0.5% Igepal over night
at 4 °C. After that the proteins were processed for immunoprecipita-
tion with antibodies against eIF4GI or the pre-immune serum,
washed 10 times with buffer A with 0.5% Igepal and analyzed by
SDS-PAGE and Western blotting.
For pep-spot analysis, a collection of 122 overlapping peptides
corresponding to the eIF4GI protein was synthesized on a cellulose
membrane as described (Valle et al., 1999). Each peptide contained
13 amino acids and had a three-amino-acid shift with the next. The
membrane was blocked with 3% low fat milk in PBS overnight at
room temperature (RT) and it was then incubated with the primary
and secondary antibodies used to detect PB2. Subsequently, the mem-
brane was incubated with His-PB2 protein (5 μg/ml) in PBS for 2 h at
RT followed by its corresponding primary and secondary antibodies.
The membrane was then incubated with the primary and secondary
antibodies used to detect VP1 and ﬁnally with His-VP1 (5 μg/ml) in
PBS for 2 h at RT followed by its corresponding primary and secondary
antibodies. After each round of incubation Western blots were carried
out and after each Western blot assay the membrane was stripped
three times in solution A (8 M urea, 1% SDS, 0,5% b-mercaptoethanol
in PBS pH-7) for 5 min at 40 °C in a sonication bath, followed by treat-
ment with stripping solution B (acetic acid, EtOH, H2O 10:50:40) with
agitation. Before the next incubation round, the stripped membrane
was examined by ECL and developed.
In vitro translation
For in vitro translation reactions, transcription of control capped
dicistronic mRNA was performed from XhoI linearized pGEM-Cap-
CAT:EMCV-IRES-Luc (which expresses the IRES element of the en-
cephalomyocarditis virus) (Pisarev et al., 2004) using the Megascript
transcription system (Ambion). Addition of the 7-mGTP cap 0 structure
was performed using ScriptCapTM m7G Capping System (Epicentre
Biotechnologies) and mRNA was poly-adenylated using poly-A poly-
merase (PAP) following the suppliers' recommendations. To obtain in-
ﬂuenza virus RNAs for in vitro translation reactions, cytosolic extracts
of infected cells were obtained 6 hpi in buffer A as described above.
Total RNA was isolated from the extracts using Ultraspec reagent
(Biotecx Laboratories).
In vitro translation reactions were performed using the Flexi rabbit
reticulocyte lysate (RRL) system (Promega), using 200 μg/ml of cyto-
solic RNA from inﬂuenza infected cells or 10 μg/ml of control dicistro-
nic RNAs. In reactions that required the addition of either
recombinant His-4E-BP1 or His-eIF4E the reactions were preincu-
bated with the recombinant proteins at 30 °C for 15 min prior to the
addition of RNA. The reactions were terminated after 90 min by the
addition of SDS-PAGE sample buffer and the products were subse-
quently resolved on 12.5% SDS-gels. In some experiments eIF4E pro-
tein was depleted from RRL as previously described (McKendrick et
al., 2001).
Ampliﬁcation and puriﬁcation of recombinant polymerase complexes
and RNPs
Recombinant RNPs containing the NS-CAT genomic RNA were
generated and ampliﬁed in vivo by transfection of plasmids, pCMV-
PB1, pCMV-PB2-His, pCMV-PA, pCMV-NP and pHH-NS-CAT in
HEK293T cells as described previously (Jorba et al., 2009). For RNP
puriﬁcation, clariﬁed cell extracts were incubated overnight at 4 °C
with 2+Ni-NTA-agarose resin in a buffer containing 50 mM Tris–HCl
(pH-8.0), 100 mM KCl, 5 mM MgCl2, 0.5% Igepal, 20 mM imidazol
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was washed with 80 volumes of this buffer and RNPs were eluted in
the same buffer containing 150 mM imidazol. In vivo reconstituted
RNPs using pCMV-PB2 (untagged) were used as control.
Recombinant polymerase complexes were obtained by transfec-
tion of plasmids pCMV-PB1, pCMV-PB2-His and pCMV-PA in
HEK293T cells that were processed and puriﬁed as described above.
Effect of rapamycin in CAT expression driven by the RNA polymerase II or
by the viral polymerase
To examine the effect of rapamycin treatment on the translation of
a CAT gene transcribed by the RNA polymerase II or the viral polymer-
ase, the scheme outlined in Fig. 5 was followed. HEK293T cells were
ﬁrst transfected with pCMV-PB1, pCMV-PB2, pCMV-PA and pCMV-
NP plasmids and 12 h later, the cells were maintained in the presence
or absence of rapamycin for 4 h before the transfection with pCMV-
CAT, pCMV-NS-CAT or recombinant His-tagged NS-CAT RNPs puriﬁed
as described above. At 7 h post transfection, total cell extracts were
prepared and used for CAT determination by ELISA assays. In each
condition, cytoplasmic RNA was isolated from the cell extracts using
TRI reagent (Sigma) to evaluate the CAT and b-actin mRNA content
by quantitative RT-PCR using the Applied Biosystems kit.
qRT-PCR mRNA detection
Cytosolic extracts were prepared as described and the RNA was iso-
lated using TRIzol (Invitrogen). RNA (2–5 μg) was then treated with
Turbo DNA-free kit (Ambion) and reverse transcribed using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems), accord-
ing to the manufacturer's instructions. Real-time PCR was performed
with SYBR green (Applied Biosystems) using an ABI Prism 7700
thermocycler with ﬂuorescence detection (Applied Biosystems). The
following pair of oligos was used for CAT mRNA detection: FW (5′-
CTGGCGATTCAGGTTCATC-3′) and RV (5′-TTTTTTTTTTTTTTTTCAGATC-
TATTACG-3′). Beta-actin mRNA was detected with: FW (5′-CCCAGCA-
CAATGAAGATCAA-3′) and RV (5′ CGATCCACACGGAGTACTTG-3′) and
used for normalization. Appropriate controls were included in each
reaction, and dissociation analysis was performed at the end of each
run to conﬁrm the speciﬁcity of the reaction.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.10.028.
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